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OBJECTIVE—Previous studies have demonstrated that the
VAMP8 protein plays a complex role in the control of granule
secretion, transport vesicle trafﬁcking, phagocytosis, and endo-
cytosis. The present study was aimed to investigate the role of
VAMP8 in mediating GLUT4 trafﬁcking and therefore insulin
action in mice.
RESEARCH DESIGN AND METHODS—Physiological param-
eters were measured using Oxymax indirect calorimetry system
in 12-week-old VAMP8 null mice. Dynamic analysis of glucose
homeostasis was assessed using euglycemic–hyperinsulinemic
clamp coupled with tracer radioactively labeled 2-deoxyglucose.
Insulin stimulated GLUT4 protein expressions on muscle cell
surface were examined by immunoﬂuorescence microscopy.
RESULTS—VAMP8 null mice display reduced adiposity with
increased energy expenditure despite normal food intake and
reduced spontaneous locomotor activity. In parallel, the VAMP8
null mice also had fasting hypoglycemia (84  11 vs. 115  4) and
enhanced glucose tolerance with increased insulin sensitivity
due to increases in both basal and insulin-stimulated glucose
uptake in skeletal muscle (0.19  0.04 vs. 0.09  0.01 mmol/kg/
min during basal, 0.6  0.04 vs. 0.31  0.06 mmol/kg/min during
clamp in red-gastrocnemius muscle, P  0.05). Consistent with a
role for VAMP8 in the endocytosis of the insulin-responsive
GLUT4, sarcolemma GLUT4 protein levels were increased in
both the basal and insulin-stimulated states without any signiﬁ-
cant change in the total amount of GLUT4 protein or related
facilitative glucose transporters present in skeletal muscle,
GLUT1, GLUT3, and GLUT11.
CONCLUSIONS—These data demonstrate that, in the absence
of VAMP8, the relative subcellular distribution of GLUT4 is
altered, resulting in increased sarcolemma levels that can ac-
count for increased glucose clearance and insulin sensitivity.
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nsulin-stimulated glucose uptake in muscle and ad-
ipose tissue is mediated by the insulin-responsive
GLUT isoform GLUT4 (1). In the basal state, 95%
of the GLUT4 protein is sequestered in intracellular
membranes (termed the insulin-responsive storage vesi-
cles) and after acute insulin stimulation undergoes a
translocation process such that 50% of the GLUT4 protein
is cell surface localized (2–5). There is now good evidence
that vesicle fusion reactions are initiated by interactions
among SNARE proteins (soluble N-ethylmaleimide-sensi-
tive factor attachment protein receptors) that assemble
into a four-helix bundle between the transport and accep-
tor membranes (6–8). It is generally accepted that the
plasma membrane t-SNARE is composed of syntaxin 4 and
SNAP23 whereas the v-SNARE present in GLUT4 vesicles
is VAMP2 (9–15), although a recent study has suggested
that several VAMP proteins can play redundant roles in
this process (16). Endobrevin or VAMP8 was originally
identiﬁed as an endosomal v-SNARE that mediated the
homotypic fusion of early and late endosomes (13,17–21).
Subsequently, VAMP8 was found to be present on several
membrane compartments including early and late endo-
somes as well as the plasma membrane, trans-Golgi
network, clathrin-coated pits, and secretory granules
(15,19,22,23). VAMP8 was found to be required for mast
cell degranulation, zymogen granule release from pancre-
atic acinar cells, and dense core granule release from
platelets, suggesting that VAMP8 functions in plasma
membrane exocytosis (13,19,24–28). On the other hand, it
has been recently reported that VAMP8 functions to inhibit
phagocytosis in immature dendritic cells, to induce mem-
brane rufﬂes and bacterial entry into nonphagocytic cells,
and for the efﬁcient endocytosis of the plasma membrane
GLUT4 protein in adipocytes (16,29). Thus, VAMP8 ap-
pears to have several functions that may be dependent
upon the particular cell type and/or trafﬁcking cargo
material.
To further investigate the role of VAMP8, we have taken
advantage of the VAMP8 null mouse (19) to examine the
integrative physiology of glucose metabolism and GLUT4
trafﬁcking in skeletal muscle in vivo. These data demon-
strate that VAMP8 plays multiple roles in the whole-body
regulation of metabolism, energy expenditure, and insulin
sensitivity. Consistent with a role of VAMP8 in mediating
GLUT4 endocytosis, skeletal muscle sarcolemma levels of
GLUT4 were elevated in the VAMP8 null mice, directly
accounting for the increase in both basal and insulin-
stimulated glucose uptakes.
RESEARCH DESIGN AND METHODS
Animals. The control and VAMP8 knockout mice were maintained in a mixed
C57BL/6J-129SvJ background (19) for over 11 generations and were housed in
a temperature-controlled environment with a 12-h light/12-h dark cycle. Food
intake and weights were determined daily, and all studies were performed on
12–14-week-old male mice. All animal protocols were performed in accor-
dance with Albert Einstein College of Medicine of Yeshiva University IACUC
(Institutional Animal Care and Use Committee) approval.
Indirect calorimetry. Metabolic measurement was performed using an
Oxymax indirect calorimetry system (Columbus Instruments, Columbus, OH)
(30). Mice were individually housed in the chamber with a 12-h light/12-h dark
cycle in an ambient temperature of 22–24°C. VO2 and VCO2 rates were
determined under Oxymax system settings as follows: air ﬂow, 0.6 l/min;
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30 DIABETES, VOL. 60, JANUARY 2011 diabetes.diabetesjournals.orgsample ﬂow, 0.5 l/min; settling time, 6 min; and measuring time, 3 min. The
system was calibrated against a standard gas mixture to measure O2 con-
sumed (VO2, ml/kg/h) and CO2 generated (VCO2, ml/kg/h). Metabolic rate
(VO2), respiratory quotient (ratio of VCO2/VO2), and activity (counts) were
evaluated over a 24-h period. Energy expenditure was calculated as the
product of the caloriﬁc value of oxygen (3.815  1.232  respiratory quotient)
and the volume of O2 consumed.
In vivo assessment of insulin action and glucose metabolism. Five days
before the experiment, the mice were anesthetized with ketamine (100 mg/kg)
and xylazine (10 mg/kg), and two indwelling catheters with preﬁlled heparin
(1,000 units/ml) and polyvidone–povidone (0.5 g/ml; Sigma) were introduced
in the right internal jugular vein and left carotid artery. The catheters were
externalized through an incision in the skin ﬂap behind the head, and the mice
were returned to individual cages after the surgery. The mice were fully
recovered from the surgery before the in vivo experiments, as reﬂected by
their reaching preoperative weight.
Euglycemic–hyperinsulinemic clamp. After a 12-h fast, euglycemic–hyper-
insulinemic clamps were conducted in conscious mice as previously
described (31,32) with minor modiﬁcation. The 2-h euglycemic–hyperinsuline-
mic clamp was conducted with a continuous infusion of human insulin (4
m/kg/min) and a variable infusion of 25% glucose to maintain glucose at 90
mg/dl. Insulin-stimulated whole-body glucose metabolism was estimated
using continuous infusion of [3-
3H]glucose (0.1 Ci/min; PerkinElmer Life
Sciences). To determine the rate of basal glucose turnover, [3-
3H]glucose (0.05
Ci/min) was infused for 2 h (basal period) with 5 Ci bolus before starting
the euglycemic–hyperinsulinemic clamp, and a blood sample was taken at the
end of this basal period. To assess insulin-stimulated tissue-speciﬁc glucose
uptake, 2-deoxy-d-[1-
14C]glucose 2-[
14C]DG (PerkinElmer Life Sciences) was
administered as a bolus (10 Ci) 75 min after the start of the clamp. Blood
samples were taken at time 0 and every 10 min from 80–120 min through the
carotid artery. To estimate basal muscle glucose uptake, 2-[
14C]DG glucose
was infused with isotonic saline. During the clamp, plasma glucose was
monitored using 2 l of blood by glucose meter (precision Xtra, Abbot,
Bedford, MA). Plasma [3-
3H]glucose, 2-[
14C]DG glucose, and
3H2O concentra-
tion were measured as described previously (31). After the euglycemic–
hyperinsulinemic clamp, individual tissue samples were collected and
immediately frozen at 80°C for the measurement of glucose uptake.
Oral glucose tolerance test. Mice fasted for 12 h were administrated
glucose (1g/kg) by oral gavage. Plasma samples were collect at 0, 30, 60, and
120 min for glucose and insulin levels. Glucose was measured using a glucose
meter (precision Xtra, Abbot, Bedford, MA). Insulin levels were determined by
ELISA (Crystal Chem Inc., Downers Grove, IL).
Dynamic glucose disposal. The stable isotope-labeled intraperitoneal glu-
cose tolerance test (SipGTT) was performed as previously described (33).
Brieﬂy, male wild-type and VAMP8 null mice were overnight fasted and were
given a 1.0 g/kg intraperitoneal injection of glucose (containing 50% [6,6-
2H2]-
glucose). The amount of the M2 label in the C3–C6 fragment for [6,6-
2H2]glucose was determined by electron impact ionization mass spectrometry,
after conversion of the glucose to a glucose aldonitrile pentaacetate derivative
(34).
Acute insulin stimulation. For acute insulin stimulation, the mice were
fasted for 12 h and given either isotonic saline or human recombinant insulin
(1U/kg) by intraperitoneal injection. Fifteen min later the animals were
anesthetized with pentobarbital sodium (50 mg/kg), and tissue samples were
collected and subjected to immunoblotting and immunoﬂuorescence.
Immunoblotting. Tissues isolated from acute insulin stimulation were ho-
mogenized in ice-cold lysis buffer (50 mmol/l Tris, pH 7.5, 150 mmol/l NaCl, 1%
Triton X-100, 1 mmol/l EDTA, 1 mmol/l phenylmethylsulfonyl ﬂuoride, 0.25%
sodium deoxycholate, 1 mmol/l NaF, 1 mmol/l Na3VO4, and 2 mmol/l Na4P2O7)
containing a protease inhibitor mixture (Roche Diagnostics). The resultant
lysates were centrifuged at 16,000g for 60 min at 4°C, and protein concentra-
tions were quantiﬁed using the bicinchoninic acid protein assays (Pierce). The
protein samples (30 g) were separated on a 4–12% gradient SDS-PAGE gel
and transferred to nitrocellulose membranes using a semidry electroblotter
(Owl Separation System, Portsmouth, NH). Membranes were immunoblotted
with a VAMP8 polyclonal (18). Other antibodies were purchased from
commercial suppliers: GLUT4 polyclonal antibody (East Acres Biologicals
Inc.), GLUT1, -3, and -11 (Cell Signaling Technology, Inc.), UCP-1, UCP-2
(Abcam Inc.), and UCP-3 (Sigma). Quantiﬁcation of all immunoblots was
performed using NIH IMAGE software.
Immunoﬂuorescence microscopy. Tissues isolated from acute insulin stim-
ulation were embedded in optimal cutting temperature compound. The frozen
tissue cross sections (10 m) were blocked with 3% BSA in PBS for 60 min at
room temperature. Primary antibodies were used at the following dilutions:
GLUT4 polyclonal antibody (1:100) and -dystroglycan (-DG) antibody (1:50)
as previously described (35). Fluorescently conjugated secondary antibodies
(1:100, Jackson ImmunoResearch Laboratories) were added to the sections
for 30 min at room temperature. After extensive washing with PBS, the slides
were mounted with Vectashield Mounting Medium (Vector Laboratories). The
slides were visualized by confocal ﬂuorescent microscopy (model LSM510;
Carl Zeiss MicroImaging, Inc.). Quantiﬁcation of cell surface immunoﬂuores-
cence was performed using NIH IMAGE software.
Statistical analysis. Results are presented as the means  SEM. Statistical
signiﬁcance was determined using an unpaired two-tailed Student t test, with
P  0.05 considered signiﬁcant.
RESULTS
VAMP8 null mice have reduced adiposity. To examine
the metabolic phenotype of the VAMP8 null mice, we ﬁrst
determine total body weight, total water, and lean and fat
mass of male VAMP8 null mice compared with wild-type
controls by quantitative nuclear magnetic resonance non-
invasive imaging (Fig. 1). The VAMP8 null mice had
reduced total body weight with no statistically signiﬁcant
difference in lean mass or total water content compared
with control mice. In contrast, there was a marked reduc-
tion in total fat mass (Fig. 1A). This occurred despite
normal caloric intake during both the light and dark
cycles, and if normalized for body weight the VAMP8 null
mice in fact have an approximate 10% increase in food
intake (Fig. 1B). These observed changes in fat mass were
conﬁrmed by tissue dissection that conﬁrmed no signiﬁ-
cant difference in gastrocnemius muscle (Fig. 1C) or liver
(Fig. 1D) weight but with a marked reduction in epididy-
mal adipose tissue mass (Fig. 1E). The reduced adiposity
resulted from a large reduction in adipocyte cell size as
observed by histological imaging (supplementary Fig. 1,
available in an online appendix at http://diabetes.
diabetesjournals.org/cgi/content/full/db10-0231/DC1).
Because changes in adipocyte cell size have been
correlated with changes in the secretion and plasma
levels of different cytokines, we next determined the
plasma levels of leptin, resistin, retinol binding protein
4 (RBP4), and adiponectin in the fasted state (Fig. 2).
Consistent with reduced adipocyte cell size in the
VAMP8 null mice, leptin and RBP4 levels were signiﬁ-
cantly decreased whereas adiponectin levels were
somewhat increased. However, there was no signiﬁcant
difference in plasma resistin levels between the VAMP8
null and wild-type control mice.
VAMP8 null mice display increased energy expendi-
ture and insulin sensitivity. Because the VAMP8 null
mice have reduced adiposity despite equivalent or slightly
enhanced daily caloric intake, we hypothesized that these
mice would display increased energy expenditure. This
speculation would be consistent with increased levels of
adiponectin. To determine whole-body energy expendi-
ture, wild-type and VAMP8 null mice were subjected to
indirect calorimetry (Fig. 3). Oxygen consumption was
increased during both the light and dark cycles, resulting
in a total 24-h increase corresponding to a 40% increase in
total energy expenditure (Fig. 3A and B). The increased
energy expenditure was also apparent when corrected for
lean body mass (supplementary Fig. 5). This increase in
energy expenditure also occurred even though the VAMP8
null mice also displayed a decrease in locomotor activity
during the dark cycle (Fig. 3C).
Because increased energy expenditure can result from
mitochondrial uncoupling, we examined the expression of
UCP-1/2/3 in skeletal muscle and adipose tissue (supple-
mentary Fig. 2, available in an online appendix). There was
no signiﬁcant difference in UCP-1 protein levels between
wild-type and VAMP8 null mice in brown adipose tissue,
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cle, although we were unable to detect UCP-1 protein in
white gastrocnemius skeletal muscle. Similarly, there was
no change in UCP-3 levels in any of the tissues examined.
In contrast, UCP-2 protein levels were increased in white
gastrocnemius skeletal muscle of the VAMP8 null mice
with no change in white adipose tissue or red gastrocne-
mius skeletal muscle.
In any case, the increase in energy expenditure and
reduced adiposity resulted in marked enhancement of
glucose tolerance along with a decrease in fasting plasma
glucose levels (Fig. 4A). Although insulin levels were
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FIG. 1. VAMP8 null mice have a selective reduction in adipose tissue mass with normal food intake. A: Total adipose tissue and lean and water
mass were determined in 12-week-old male wild-type (WT, open boxes) and VAMP8 null (VAMP8, ﬁlled boxes) mice by quantitative nuclear
magnetic resonance. B: The average caloric intake of a normal chow diet during both the light and dark cycle was determined in an Oxymax
open-circuit indirect calorimetry system over a 4-day period. C: Gastrocnemius skeletal muscle mass, (D) liver mass, and (E) epididymal adipose
tissue mass per total body weight were determined by dissection and weighing of the individual tissues. These data represent the mean  SEM
from ﬁve individual mice per group. *P < 0.05.
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FIG. 2. VAMP8 null mice have changes in plasma levels of several adipokines. Fasting plasma levels of (A) leptin, (B) RBP4, (C) resistin, and (D)
adiponectin in WT (open boxes) and VAMP8 (ﬁlled boxes) mice were determined by ELISA analysis. These data represent the mean  SEM from
six mice per group. *P < 0.02.
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oral glucose tolerance test, the changes in insulin levels
paralleled the changes in plasma glucose, suggesting that
total pancreatic 	-cell insulin secretion was not signiﬁ-
cantly affected (Fig. 4B). Similarly, SipGTT demonstrated
a greater clearance of glucose in the VAMP8 null mice
compared with controls (Fig. 4C). Quantiﬁcation of the
area under the curve showed that the VAMP8 null mice
display a reduction in glucose excursion, increased glu-
cose disposal with a concomitant reduction in total insulin
secretion levels (Fig. 4D).
To speciﬁcally determine whether the VAMP8 null mice
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FIG. 3. Loss of VAMP8 expression results in increased energy expenditure (EE). Fourteen-week-old WT (open boxes) and VAMP8 (ﬁlled boxes)
mice were placed into Oxymax open-circuit indirect calorimetry system over a 4-day period. The mice were fed in the 12-h dark cycle, and food
was restricted during the 12-h light cycle. The average oxygen consumption in ml/kg/h (A) and energy expenditure in kcal/g/h (B) were
determined. **P < 0.003. C: Spontaneous locomotor activity in the x, y, and z planes were determined as the total number of beam brakes. These
are the averages from ﬁve WT and four VAMP8 mice. *P < 0.05.
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FIG. 4. VAMP8 mice display enhanced glucose tolerance. Twelve-week-old WT (open circles) and VAMP8 (ﬁlled circles) were fasted for 14 h and
given 1 g/kg of D-glucose in isotonic saline by oral gavage. Blood (10 l) was collected from the tail vein at 0, 30, 60, and 120 min. The blood glucose
(A) and insulin (B) levels were determined and represent the mean  SEM from ﬁve individual mice per group. *P < 0.05, **P < 0.003. C:
Twelve-week-old WT and VAMP8 mice were fasted for 15 h and given an intraperitoneal injection of 1g/kg of D-glucose 50% enriched with
[6,6-
2H2]-glucose. Each point represents the mean  SEM from four individual mice per group. *P < 0.05, **P < 0.001. D: The area under the curve
for blood glucose and insulin levels were calculated from the glucose and glucose isotopomers measured during the SipGTT.
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scious nonstressed euglycemic–hyperinsulinemic clamps.
As observed during the oral glucose tolerance test, in the
basal or fasting level of plasma, glucose was reduced in the
VAMP8 null mice compared with wild-type control and
was normalized to the same level (90 mg/dl) during the
euglycemic–hyperinsulinemic clamp (Fig. 5A). Similarly,
plasma insulin was normalized to the same hyperinsuline-
mic levels during the euglycemic–hyperinsulinemic clamp
for both the wild-type and VAMP8 null mice (Fig. 5B).
Consistent with an increase in insulin sensitivity, the
glucose infusion rate during the euglycemic–hyperinsu-
linemic clamp was greater in the VAMP8 null mice along
with increased whole-body glucose uptake (Fig. 6A and B).
The overall rate of body glycogen/lipid synthesis was also
increased with no statistically signiﬁcantly change in total
body glycolysis rate, although there was a consistent
increased trend in the VAMP8 null mice (Fig. 6C and D).
Skeletal muscle accounts for the majority of glucose
postprandial glucose uptake and was signiﬁcantly in-
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FIG. 6. VAMP8 mice have increased whole-body insulin sensitivity, glucose uptake, and glycogen/lipid synthesis. WT (open boxes) and VAMP8
(ﬁlled boxes) were subjected to euglycemic–hyperinsulinemic clamps to determine (A) the glucose infusion rate (GIR) necessary to maintain
euglycemia. B: Whole-body glucose uptake was determined as [3-
3H]-glucose speciﬁc activity tracer infusion rate and weight of mice in the basal
or euglycemic–hyperinsulinemic clamp state. C: The whole-body glycolysis was determined from the increment of the plasma
3H2O concentration
multiplied by the estimated body water divided by [3-
3H]-glucose speciﬁc activity. D: The glycogen/lipid synthesis was estimated as the difference
between whole-body glucose uptake and whole-body glycolysis. These data represent the mean  SEM from 7–10 individual mice per group. *P <
0.05.
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gastrocnemius) in both the basal and insulin-stimulated
states (Fig. 7A). In parallel, insulin induced a greater
suppression of hepatic glucose output in the VAMP8 null
mice (Fig. 7B).
VAMP8 null mice have increased sarcolemma levels
of glut4 protein. Because the VAMP8 null mice displayed
increased insulin-stimulated glucose uptake and fasting
hypoglycemia, we speculated that the sarcolemma distri-
bution of GLUT4 might be increased. To examine this
possibility, red gastrocnemius muscle from overnight-
fasted wild-type and VAMP8 null mice were ﬁxed and
subjected to confocal immunoﬂuorescence for the endog-
enous GLUT4 protein (Fig. 8A). The muscle ﬁber from the
VAMP8 null mice displayed an increase in the cell surface
distribution of GLUT4 as colocalized with the sarcolemma
marker protein -DG. The increased muscle cell surface
distribution of GLUT4 in the VAMP8 null mice was even
more pronounced in the insulin-stimulated state (Fig. 8B).
Quantiﬁcation of these data demonstrated a statistically
signiﬁcant increase in the sarcolemma GLUT4 protein of
the VAMP8 null mice in the basal and insulin-stimulated
states (Fig. 8C). Similar to that in the gastrocnemius
muscle, confocal immunoﬂuorescence of soleus muscle
FIG. 7. VAMP8 mice have increased skeletal muscle glucose uptake with decreased hepatic glucose output (HGO). A: Basal and insulin-stimulated
glucose uptake into skeletal muscle tissues (soleus and red gastrocnemius [GAS-R]) were determined by 2-deoxy-D-[1-
14C] glucose injection
during the last 35 min of saline (basal) or insulin infusion during the euglycemic–hyperinsulinemic clamp. B: The insulin suppression of HGO was
determined during the euglycemic–hyperinsulinemic clamp by [3-
3H]-glucose infusion. These data represent the mean  SEM from 5–10 individual
mice per group. *P < 0.05.
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FIG. 8. VAMP8 (V8) mice have increased GLUT4 protein localized to the sarcolemma membrane in GAS-R skeletal muscle. WT and VAMP8 mice
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images are shown, and quantiﬁcation of the relative extent of cell surface distribution of GLUT4 (C) was determined as the mean  SEM from
5–10 independent mice. *P < 0.05, **P < 0.003, WT mice (open boxes), and VAMP8 mice (ﬁlled boxes). (A high-quality digital representation of
this ﬁgure is available in the online issue.)
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sarcolemma GLUT4 localizations in the VAMP8 null mice
compared with the control wild-type mice (supplementary
Fig. 3, available in an online appendix). This change in
GLUT4 subcellular distribution occurred with no signiﬁ-
cant change in the total expression levels of the GLUT4
protein or the total protein levels of several other facilita-
tive glucose transporters GLUT1, GLUT3, and GLUT11
(supplementary Fig. 4, available in an online appendix).
DISCUSSION
Loss of VAMP8 protein levels results in the impairment of
multiple distinct membrane-trafﬁcking processes includ-
ing the terminal membrane fusion event of cytokinesis,
zymogen granule release in pancreatic acinar cells, de-
granulation of mast cells, transcytosis in polarized epithe-
lial cells, secretory granule release from platelet and
cytotoxic T-cells, and the plasma membrane exocytosis of
the cystic ﬁbrosis membrane conductance regulator and
the aquaporin 2 water channel (21,23,25,26,28,29,36–41).
In contrast, other studies have reported alternative roles
for VAMP8 in membrane trafﬁcking. For example, VAMP8
function is necessary for homotypic fusion of early and
late endosomes, endosome–lysosome fusion, enhanced
vesicle recycling between endocytic vesicles and the en-
dosome in pancreatic 	-cells, and GLUT4 endocytosis in
adipocytes (15,17,20,21).
To examine the physiologic role of VAMP8 in glucose
homeostasis in vivo, we took advantage of the VAMP8 null
mice (19). Surprisingly, despite the alterations of different
intracellular trafﬁcking events, these mice displayed a
marked reduction in adipocyte cell size with increased
secretion levels of the adipokine adiponectin that favor
enhanced glucose metabolism through increased fatty acid
oxidation (42–45). More remarkably, the VAMP8 null mice
have reduced spontaneous activity with identical caloric
intake compared with the wild-type mice, yet rather than
gaining adipose tissue mass, the VAMP8 null mice are
leaner apparently due to increased total body energy
expenditure. The increase in whole-body energy expendi-
ture was not due to changes in adipose tissue or skeletal
muscle UCP-1 or UCP-3 expression. Although UCP-3 is the
predominant isoform present in skeletal muscle with
lower levels of UCP-2 (46,47), we observed a signiﬁcant
increase in UCP-2 protein levels speciﬁcally in white
gastrocnemius skeletal muscle of the VAMP2 null mice.
Thus, it remains possible that the elevated UCP-2 levels
account for the increase in energy expenditure, and the
reduced size of adipocytes could result from an increased
demand of skeletal muscle for fatty acid oxidation. Future
studies will be necessary to directly assess this possibility
and the mechanism responsible for the tissue-speciﬁc
UCP-2 induction.
The enhanced metabolic balance of the VAMP8 null
mice was also reﬂected in increased whole-body glucose
tolerance and insulin sensitivity. Although there was a
small enhancement in insulin suppression of hepatic glu-
cose output, the major effect was a marked increase in
skeletal muscle glucose uptake in both the basal and
insulin-stimulated states. The increase in glucose uptake
in the basal state is also consistent with the relative fasting
hypoglycemia in the VAMP8 null compared with wild-type
mice. Mechanistically, the loss of VAMP8 resulted in a
greater distribution of the skeletal muscle GLUT4 protein
at the sarcolemma membrane in the basal state that is
consistent with the increase in basal glucose uptake.
Similarly, the greater extent of insulin-stimulated GLUT4
translocation to the sarcolemma is also consistent with the
increase in insulin-stimulated glucose uptake. The in-
crease in cell surface GLUT4 levels occurred without any
change in total GLUT4 protein levels. Thus, the loss of
VAMP8 function could result in either an increase in the
rate of GLUT4 exocytosis and/or a decrease in sarco-
lemma GLUT4 endocytosis. As we have previously ob-
served that VAMP8 has no effect on GLUT4 exocytosis but
is required for efﬁcient GLUT4 endocytosis in 3T3L1
adipocytes (15), these data provide in vivo support for
VAMP8 providing a necessary function in the cell surface
endocytosis of the GLUT4 protein.
The glucose metabolic characteristics in the VAMP8 null
mice are remarkably analogous to transgenic mice over-
expressing the GLUT4 gene both in normal GLUT4 target
tissues and speciﬁcally in skeletal muscle (48–51). In all
these models, overexpression of GLUT4 resulted in in-
creased cell surface levels of the GLUT4 protein that
resulted in reduced fasting glycemia, increased skeletal
muscle glycogen content, and improved glucose tolerance
and insulin sensitivity in peripheral tissue. This enhanced
glucose handling previously reported for GLUT4 trans-
genic mice parallels the same reduction in fasting glucose,
increased glycogen synthesis, and increased insulin sensi-
tivity and glucose tolerance observed in the VAMP8 null
mice. Moreover, the reduction in insulin levels that follows
the reduction in plasma glucose was accompanied by
compensatory lipolysis that is also consistent with the
reduction of adipocyte cell size observed in the VAMP8
null mice
Although all these metabolic data are consistent with
VAMP8 playing a role in modulating skeletal muscle cell
surface GLUT4 levels, how then do we also account for the
observations that a variety of exocytotic secretory events
are inhibited in VAMP8 null mice? One simple possibility is
that VAMP8 plays different roles in the membrane trafﬁck-
ing of different cell types and/or for different cargo pro-
teins. Alternatively, a more interesting possibility is the
presence of a direct coupling between the endocytosis and
exocytosis processes. Previously, it was reported that
inhibition of chromafﬁn cell endocytosis by blocking dy-
namin function with a dynamin antibody resulted in a
progressive decrease in catecholamine release (52). Simi-
larly, blockade of dynamin function with a dominant-
interfering mutant or reduction in dynamin protein levels
by siRNA resulted in relatively normal initiation of ﬁrst-
phase secretion but that was subsequently inhibited along
with the more prolonged inhibition of second-phase secre-
tion in cultured 	-cells (53). These data suggest the
presence of a direct coupling between granule exocytosis
(fusion pore opening) and endocytosis (fusion pore clo-
sure) events. Thus, another possibility is that the extent of
membrane exocytosis is directly coupled to endocytosis in
a manner necessary to prevent unrestricted expansion of
the plasma membrane surface area. In this case, blockade
of VAMP8 function also results in an inhibition of mem-
brane exocytosis via a feedback mechanism arising from
the prevention of normal membrane endocytosis and
recycling.
In either case, the data presented demonstrate that the
loss of VAMP8 expression has a marked effect on the
integrative physiology of glucose metabolism and energy
expenditure. These combined effects result in a leaner
mouse with increased energy expenditure and glucose
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a therapeutic strategy to inhibit VAMP8 function in skele-
tal muscle may be a viable approach to enhance glucose
homeostasis.
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